Drug intelligence / Profile preview

anti-Escherichia coli recombinant antibodies

Development stage: Preclinical
Lead developer: Erasmus MC
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

Anti-Escherichia coli recombinant antibodies are a class of complement-activating recombinant antibodies under development for potential passive immunotherapy against nosocomial bloodstream infections and sepsis. Developed through the TARAME pre-pilot translational study at Erasmus MC (Universitair Medisch Centrum Rotterdam), this program aims to identify, characterize, and clone targeted antibacterial antibodies from adult patients with active sepsis and positive blood cultures for Escherichia coli or Pseudomonas aeruginosa. By isolating and cloning these naturally occurring, complement-activating antibodies, researchers hope to establish a platform for passive immunotherapy to combat multi-drug resistant nosocomial bloodstream infections.

Other names: anti-Escherichia coli recombinant antibodiesTARAME recombinant antibodies

Targets

eaeA (Gamma-intimin)OPS (O-polysaccharide)EspA (Type III secretion system protein EspA)

Beyond the preview

Go deeper on anti-Escherichia coli recombinant antibodies.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-Escherichia coli recombinant antibodies.

Explore the full profile